tbuckley/cabot-search huggingface dataset:
角膜組織工学への応用のためのカスタマイズ可能な剛性および分解によりナノパターン化した基質としての逐次架橋生物活性ヒドロゲル【Powered by NICT】
Authors: Rizwan Muhammad, S L Peh Gary, Ang Heng-Pei, Lwin Nyein Chan, Adnan Khadijah, S Mehta Jodhbir, Tan Wui Siew, K F Yim Evelyn
Journal: Biomaterials (2017)
Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas
Authors: Aniket S. Wadajkar, Jimena G. Dancy, Nathan B. Roberts, Nina P. Connolly, Dudley K. Strickland, Jeffrey A. Winkles, Graeme F. Woodworth, Anthony J. Kim
Journal: Journal of Controlled Release (2017)
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
Authors: Alan Mackay, Anna Burford, Diana Carvalho, Elisa Izquierdo, Janat Fazal-Salom, Kathryn R. Taylor, Lynn Bjerke, Matthew Clarke, Mara Vinci, Meera Nandhabalan, Sara Temelso, Sergey Popov, Valeria Molinari, Pichai Raman, Angela J. Waanders, Harry J. Han, Saumya Gupta, Lynley Marshall, Stergios Zacharoulis, Sucheta Vaidya, Henry C. Mandeville, Leslie R. Bridges, Andrew J. Martin, Safa Al-Sarraj, Christopher Chandler, Ho-Keung Ng, Xingang Li, Kun Mu, Saoussen Trabelsi, Dorra H’mida-Ben Brahim, Alexei N. Kisljakov, Dmitry M. Konovalov, Andrew S. Moore, Angel Montero Carcaboso, Mariona Sunol, Carmen de Torres, Ofelia Cruz, Jaume Mora, Ludmila I. Shats, João N. Stavale, Lucas T. Bidinotto, Rui M. Reis, Natacha Entz-Werle, Michael Farrell, Jane Cryan, Darach Crimmins, John Caird, Jane Pears, Michelle Monje, Marie-Anne Debily, David Castel, Jacques Grill, Cynthia Hawkins, Hamid Nikbakht, Nada Jabado, Suzanne J. Baker, Stefan M. Pfister, David T.W. Jones, Maryam Fouladi, André O. von Bueren, Michael Baudis, Adam Resnick, Chris Jones
Journal: Cancer Cell (2017)

We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification.
Systemic radioimmunotherapy in synergy with vaccine renders antitumor effects in a preclinical model
Authors: Mala Chakraborty, Alexander Gelbard, Jorge A. Carrasquillo, Sarah Yu, Marcelo Mamede, Chang H. Paik, Kevin Camphausen, Jeffrey Schlom, James W. Hodge
Journal: Cancer Research (2006)

1165   Systemic radiotherapy, the delivery of therapeutic radionucleotides to cancer cells via monoclonal antibodies (Mab), remains an attractive, viable modality for the treatment and management of cancer. It has recently been recognized that sublethal doses of radiation alters the phenotype of the target tissue by up regulating new genes and makes tumor cells more susceptible to T cell mediated immune attack. However, this is not feasible for many metastases. Radiolabeled antibody has been shown to target tumor cells precisely and preferentially. In this report we have demonstrated a therapeutic synergy between radiolabeled antibody administration in combination with vaccine therapy. The model used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma cell line transfected with CEA. The vaccine regimen consisted of a prime and boost strategy using vaccinia and fowlpox recombinant vectors expressing CEA and three costimulatory molecules (B7-1, ICAM-1, LFA-3, designated TRICOM). One dose (100 microcurie) of Y-90 labeled COL-1 mAb, specific for CEA, in combination with vaccine therapy was capable of inhibiting 8 day established tumors. IN addition, the combination therapy resulted in a statistically significant increase in survival compared to vaccine or radiotherapy alone. Mice cured of tumors demonstrated CD4+ and CD8+ T-cell responses not only for CEA but also for other tumor-derived antigens (gp70 and and p53). Overall these results showed that targeted tumor radiation in combination with vaccine promotes effective antitumor response, which may have implications the design of future clinical trials.
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study.
Authors: Madeeha Ashraf, John M. Kirkwood, Marc S. Ernstoff, Hussein Abdul-Hassan Tawbi, Paul Henry Frankel, Nora Ruel, Kari Lynn Kendra, Thomas Olencki, Nikhil I. Khushalani, Theodore F. Logan, Kim Allyson Margolin, Alice P. Chen, Ahmad A. Tarhini
Journal: Journal of Clinical Oncology (2014)

TPS9120 Background: IL-2 plays a central role in immunity affecting the proliferation and survival of effectors of antitumor response. IL-2 at high bolus IV dosage gives a 16% response rate and durable responses in 4-5% of patients (pts) with metastatic melanoma. VEGF plays a critical role in angiogenesis and host innate and adaptive immunity. VEGF blocks maturation of dendritic cells and inhibits priming of T cell responses. High baseline serum VEGF was reported to be a predictor of non-response to HD IL-2. We developed a strategy to deplete VEGF prior to HD IL-2 to reverse the immunosuppressive impact of VEGF and enhance antitumor T cell response. Z (known as aflibercept outside the US) is a high-affinity soluble decoy VEGF receptor and potent angiogenesis inhibitor. Our phase II study of Z alone for advanced melanoma showed median OS of 16.3 months and PFS 3.7 months. Methods: NCI 8628 is a phase II trial of Z and HD IL-2 (Arm A) versus HD IL-2 alone (Arm B) randomized 2:1 respectively with accrual goal 105 pts. Arm A: consists of 3 courses (maximum) and each course consists of 2 cycles of HD IL-2 at 600,000 IU/kg IV every 8 hours for up to 14 doses (1st cycle), followed by a rest period of 1-2 weeks’ (wk) rest and readmission for HD IL-2 (2nd cycle). Z is given concurrently at 3 mg/kg IV every 2 wk, starting 2 wk prior to IL-2 in course 1. In the absence of disease progression, maintenance Z is given at 4 mg/kg every 2 wk after completion of IL-2. Arm B: patients receive HD IL-2 alone for a maximum of 3 courses (6 cycles). Eligible pts: Stage III inoperable or Stage IV (any M) melanoma . ECOG performance status of 0/1 and adequate organ function for HD IL-2. Up to two prior regimens for metastatic melanoma are allowed, and stable treated brain metastases. Response assessment follows RECIST v.1.1. Blood and tumor specimens are being collected prospectively for biomarker and mechanistic studies. Clinical trial information: NCT01258855.
ナノチューブアレイを用いたチタンワイヤインプラント:局所癌治療のための研究モデル【Powered by NICT】
Authors: Kaur Gagandeep, Willsmore Tamsyn, Gulati Karan, Zinonos Irene, Wang Ye, Kurian Mima, Hay Shelley, Losic Dusan, Evdokiou Andreas
Journal: Biomaterials (2016)
Immunoprofiling the cancer-specific humoral immune response in sera from node positive and node negative breast cancer patients
Authors: Maria Moroni, Laura Pedraza, Catherine E. Storrer, Rebecca J. Foley, Craig D. Shriver, Sathibalan Ponniah, George E. Peoples
Journal: Cancer Research (2005)

1541   Introduction: The correlation between a beneficial clinical outcome and a strong humoral immune response is being investigated in many cancers. However, very little is known about the cancer-specific humoral immune response in node negative (NN) versus node positive (NP) breast cancer patients. We screened lysates from three breast cancer cell lines by western blot using sera from NN and NP breast cancer patients and healthy controls in order to determine if the immunoreactive profile was different between these three groups. Methods: Sera from 37 individuals were investigated in this study. Of these, 17 sera samples were from healthy individuals (serving as control sera) and 20 samples were from breast cancer patients (which consisted of 11 NN samples and 9 NP samples). All sera samples were screened for antibodies to total cell lysates from three breast cancer cell lines (MCF7, AU565 and BT474) by SDS-PAGE followed by western blot analysis. Quantitative analysis of the western blots was performed with the ChemiGenius2 Bio Imager and image analysis software GeneTools. Results: A quantitative difference was seen in the number of immunoreactive bands between sera from NN and NP patients when screened against total cell lysate from AU565 and MCF7. The average number of immunoreactive bands for AU565 was 7.6 +/− 4.7 in NN and 1.3 +/− 1 in NP ( p =0.001), and for MCF7 it was 9.4 +/−6 and 0.8+/−1, respectively ( p =0.001). No such difference was observed when screening against BT474 cell lysate, which showed about an equal number of immunoreactive bands with both NN and NP sera, thereby dispelling the possibility of there being an overall lack of antibody content in the NP samples. A statistically significant difference was seen in the average number of bands between healthy controls and NN patients when screened against MCF7 (controls= 3.9 +/− 3.8 and NN= 9.4 +/− 6 bands;  p =0.009), and controls and NP when screened against AU565 (controls= 5.5 +/− 4.6 and NP= 1.3 +/− 1 bands). Conclusion: Sera immunoreactivity against MCF7 and AU565 cell lysates, but not BT474, was found to be able to distinguish, by western blot analysis, sera from NN and NP breast cancer patients. This approach of serum immunoprofiling may serve as a basis for a new non-invasive technique to determine the nodal status of breast cancer patients at time of diagnosis/follow up.
Neurological Complications of Immunotherapies—Beware of the Checkpoint Ahead
Authors: Roy E. Strowd
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 327: Utrophin Loss in the Absence of Dystrophin Induces Alterations in Cardiac-Related Protein Expression and Activity in the Heart and Muscle of Dystrophic Mice
Authors: Joel S Schneider, Jayalakshmi Ramachandran, Mayilvahanan Shanmugam, Pierre-Antoine Crassous, James P Gonzalez, Richard Gordan, Lai-Hua Xie, Annie V Beuve, Gopal J Babu, Ruben D Peluffo, Diego Fraidenraich
Journal: Circulation Research (2012)

Duchenne Muscular Dystrophy (DMD) is an x-linked recessive disorder that affects 1:3500 males. The disease is characterized by the absence of the dystrophin protein, leading to progressive muscular degeneration in both skeletal and cardiac muscle. DMD is recapitulated in mouse models, the most severe model lacking both dystrophin and its compensatory homolog, utrophin (mdx:utro). This model mimics the onset of DMD much more rapidly than mdx. Nitric oxide (NO) synthesis is significantly diminished in DMD and mdx skeletal muscle. We have identified previously unreported functional differences in neuronal nitric oxide synthase (NOS1)-related nitric oxide production in cardiac musculature in mdx:utro mice, caused by the absence of utrophin. We have quantified mechanistic differences in L-Arginine mediated nitric oxide production via NOS1 in mdx and mdx:utro myocytes isolated via Langendorff perfusion. Interestingly, L-arginine transport levels were increased in the presence of this amino acid and occurred concurrently with increases in the number of mRNA transcripts for the low-affinity cationic amino acid transporter, CAT-2A. As CAT activity is an obligate process for L-Arginine entry to the cardiac myocytes, this may represent a potential compensatory mechanism related to decreased nitric oxide production. We have also found manifestations of ectopic cardiac-related protein expression in the quadriceps muscle of mdx:utro mice. In these tissues, we have found ectopic expression of the cardiac isoform of the SERCA2a calcium pump predominantly expressed in the heart. Additionally, we have found expression of slow-twitch Type 1 cardiac myosin heavy chain, indicative of a fiber type switch event. We have shown that expression of both of these proteins is co-localized to specific muscle fibers. Our analyses indicate that the appearance of these proteins is directly correlated with the lowered expression of the fast-twitch calcium pump (SERCA1) and muscle fiber types (Type 2a and Type 2b). These findings illustrate important molecular consequences of the absence of utrophin in mouse models of DMD. Identification of compensatory corrective targets may bear important therapeutic potential in muscular dystrophy and its associated cardiomyopathy.
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
Authors: S. Temam, J. Spicer, F. Farzaneh, J.C. Soria, D. Oppenheim, M. McGurk, A. Hollebecque, J. Sarini, K. Hussain, S. Soehrman Brossard, L. Manenti, S. Evers, P. Delmar, L. Di Scala, C. Mancao, F. Feuerhake, L. Andries, M.G. Ott, A. Passioukov, J.P. Delord
Journal: Annals of Oncology (2017)
Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial
Authors: Markus K Diener, Felix J Hüttner, Meinhard Kieser, Phillip Knebel, Colette Dörr-Harim, Marius Distler, Robert Grützmann, Uwe A Wittel, Rebekka Schirren, Hans-Michael Hau, Axel Kleespies, Claus-Dieter Heidecke, Ales Tomazic, Christopher M Halloran, Torsten J Wilhelm, Marcus Bahra, Tobias Beckurts, Thomas Börner, Matthias Glanemann, Ulrich Steger, Frank Treitschke, Ludger Staib, Karsten Thelen, Thomas Bruckner, André L Mihaljevic, Jens Werner, Alexis Ulrich, Thilo Hackert, Markus W Büchler, Inga Rossion, Alexandra Kunz, Evelin Hund, Ronald Limprecht, Hans Jürgen Schlitt, Joachim Mössner, Christoph M Seiler, Gabriele Ihorst, Pierluigi Di Sebastiano, Helmut Witzigmann, Fritz Klein, Heike Berthold, Heike Körnlein, Ulrich Hopt, Olivia Sick, Tobias Keck, Lars Ivo Partecke, Sebastian Peters, Markus M Lerch, Barbara Maichle, Birgit Erni, Sabine Bunjes-Schmieger, Sarah Igel, Svenja Stemmle, John P Neoptolemos, Michael G T Raraty, Miha Petric, Marco Niedergethmann, Claudia Schwarzmeier, Bernhard Renz, Brigitte Schreib, Wolfgang E Thasler, Michael H Schoenberg, Helmut Friess, Daniel Reim, Güralp O Ceyhan, Monika Diehl-Bein, Thomas Simon, Tobias Gehrig, Marion Hoffer, Christoph Thomas Germer
Journal: The Lancet (2017)
ヒト多能性幹細胞からの心筋コミットメント:ヒト心臓移植片の迅速な産生【Powered by NICT】
Authors: Garreta Elena, de Onate Lorena, Fernandez-Santos M. Eugenia, Oria Roger, Tarantino Carolina, M Climent Andreu, Marco Andres, Samitier Mireia, Martinez Elena, Valls-Margarit Maria, Matesanz Rafael, A Taylor Doris, Fernandez-Aviles Francisco, Izpisua Belmonte Juan Carlos, Montserrat Nuria
Journal: Biomaterials (2016)
Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content
Authors: Susanna Brauner, Xintong Jiang, Gudny Ella Thorlacius, Anna M Lundberg, Therese Östberg, Zhong-Qun Yan, Vijay K Kuchroo, Göran K Hansson, Marie Wahren-Herlenius
Journal: Cardiovascular Research (2017)

Abstract Aims Patients with hyperlipidemia are at risk of atherosclerosis, but not all develop cardiovascular disease, highlighting the importance of other risk factors such as inflammation. Both the innate and adaptive arms of the immune system have been suggested in the initiation and propagation of plaque formation. Tri-partite motif (TRIM) 21 is a regulator of tissue inflammation and pro-inflammatory cytokine production, and has been implicated in chronic inflammatory disease. Here, we investigate a potential role for TRIM21 in coronary artery disease. Methods and results Trim21-deficient or wild-type bone marrow was transplanted into Ldlr-/- mice fed a hypercholesterolemic diet. The Trim21-/--&gt;Ldlr-/- mice developed larger atherosclerotic plaques, with significantly higher collagen content compared to mice transplanted with wild-type cells. High collagen content of the atheroma is stabilizing, and has recently been linked to IL-17. Interestingly, Trim21-/--&gt;Ldlr-/- mice had elevated CD4 and IL-17 mRNA expression in plaques, and increased numbers of activated CD4+ T cells in the periphery. An increased differentiation of naïve T cells lacking Trim21 into Th17 cells was confirmed in vitro, with transcriptomic analysis revealing upregulation of genes of a non-pathogenic Th17 phenotype. Also, decreased expression of matrix metalloproteinases (MMPs) was noted in aortic plaques. Analysis of human carotid plaques confirmed that TRIM21 expression negatively correlates with the expression of key Th17 genes and collagen, but positively to MMPs also in patients, linking our findings to a clinical setting. Conclusion In this study, we demonstrate that TRIM21 influences atherosclerosis via regulation of Th17 responses, with TRIM21 deficiency promoting IL-17 expression and a more fibrous, stable, phenotype of the plaques.
Abstract 170: Re-evaluation of Carotid Intima-Media Thickness by Z-score in Children and Adolescents After Kawasaki Disease
Authors: Nobutaka Noto, Masataka Kato, Yuriko Abe, Hiroshi Kamiyama, Kensuke Karasawa, Mamoru Ayusawa, Shori Takahashi
Journal: Circulation (2015)

Objectives: The carotid intima-media thickness (CIMT) is a reliable screening method for vascular alterations even in a pediatric cohort; however, reference values of CIMT established recently by LMS methods for childhood and adolescence are limited when comparing patients after Kawasaki disease (KD) and controls. We tested the hypothesis that there are significant differences between the values of CIMT expressed as absolute values and z-scores in children and adolescents after KD and controls. Methods: We reviewed 12 published articles regarding CIMT on patients after KD and controls. Absolute values (Ab) of the mean±1 SD of CIMT in patients after KD and controls were transformed to z-scores (Zs) using age-specific reference values established by Jourdan et al. (J: 247 Caucasian subjects aged 10-20 years) and our own data (O: 175 Asian subjects aged 6-20 years), and the results were compared between the two references. In this study, the mean age of the study population derived from each article was designated the representative age for transformation. Results: In either reference (J) or (O), there was no significant sex difference in CIMT at any given age. The mean CIMT of (Ab) and (Zs) transformed by (J) or (O) were significantly different between patients after KD and controls, at 41.6% (Ab), 66.6% (Zs) by (J), and 83.3% (Zs) by (O) among 12 articles, respectively. Therefore, patients after KD had significantly higher (Zs) by (O) than those of controls (0.66±0.71 vs. 0.03±0.68, p=0.006, respectively). Compared with reference values, the controls of (O) were within the normal range. However, there were no significant differences in (Zs) by (J) between the two groups (1.72±0.77 vs. 1.23±0.83, p=0.116, respectively). When we assessed 9 articles dealing with Asian subjects, the difference of (Zs) between the two groups remained significant only by (O) (p=0.015). In contrast, when we assessed 3 articles dealing with mainly Caucasian subjects, there was no significant difference in (Zs) between the two groups with both (J) and (O). Conclusions: These results indicate that age and race-specific reference values for CIMT are mandatory for performing an accurate assessment of the vascular status in healthy children and adolescents and particularly in those after KD.
Rules for NHS compensation are to change again after costs spiral
Authors: Clare Dyer
Journal: BMJ (2017)

The UK government is again to change the method for setting the personal injury discount rate, after deciding that the last change, made six months ago, has overcompensated people who have been seriously injured through negligence.1

The rate, the notional return to be expected from investing a lump sum award, is used in calculating payouts for injury, including those for clinical negligence. It is intended to provide full compensation, neither more nor less.

Calculated in relation to the retail price index, the rate was slashed last March from 2.5%, set in June 2001, to −0.75%, causing the NHS compensation …
Abstract 2090: Health Related Quality of Life Outcomes of Therapeutic Life Style Modification Program for Women with Metabolic Syndrome
Authors: Eui Geum Oh, Soo Hyun Kim, So Yeon Bang, Sa Saeng Hyun, Yong Kwan Jeon, Jee Aee Im, Mi Kyung Lee, Jung Eun Lee, Sang Hui Chu
Journal: Circulation (2008)

Background: The metabolic syndrome (MetS), with associated increased CHD risk, is highly prevalent among postmenopausal women in Korea. Although therapeutic lifestyle modification (TLM) has been recommended as a cornerstone therapy, studies investigating the effects of TLM on health related quality of life (HRQOL) are limited. Purpose : This study was to evaluate HRQOL outcomes of a six-month TLM in Korean women with Mets. Methods: A randomized controlled design was used. Fifty four women (mean age of 63.2 y) with Mets were recruited from community health centers and randomly assigned to the intervention (N=31) or control (N=23) groups. The subjects in the intervention group participated in a supervised weekly TLM session for six months. The TLM program was consisted of health monitoring, education, aerobic exercise (40-min/session, 200 Kcal/day), and a low calorie diet with low carbohydrate (≈1300Kcal/d). Those in the control group received a booklet about MetS and were instructed to maintain their usual diet and activities. HRQOL was measured using the MOS SF-36 at before, during (month 3), completion (month 6), and after completion of the TLM program (month 12). Mixed-model repeated measures ANCOVA was used to evaluate HRQOL outcomes. Results : There were significant group by time interactions for general health ( P = .043) and vitality ( P = .012). Both general health (mean 23-point change) and vitality scores (mean 16-point change) greatly improved in the treatment group over 6 months of TLM, compared with control group. However, the improvement of the general health and vitality in the experimental group was not sustained at month 12. There were significant treatment main effects (all P &lt; .05) for the remaining SF-36 subscale scores. Conclusion : A systematic TLM program may be effective strategy for improving HRQOL in postmenopausal women with MetS.
Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178–211
Authors: Silke Gillessen, Johann S. de Bono, Oliver Sartor, Aurelius Gabriel Omlin
Journal: European Urology (2017)